Navigation Links
Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars
Date:1/15/2014

Toronto, Canada (PRWEB) January 15, 2014

This webinar will focus on EMA and FDA regulatory perspectives on nonclinical and clinical safety assessment in biosimilars.

Regulatory frameworks are evolving many countries to guide a path for biosimilar drug development, however the complex nature of biopharmaceuticals makes the demonstration of biosimilarity with regards to quality, safety and efficacy extremely challenging. Based on the specific aspects of biosimilar drug development and registration, development strategies differ significantly from the development of an innovator product that has to establish both the efficacy and safety independently from other products.

The webinar will review:

  •     EMA guidelines on Biosimilar mAbs
  •     EMA vs. FDA regulation including a discussion of WHO guidance
  •     Current global regulatory environment
  •     Case studies and ongoing challenges

A live Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit: http://xtalks.com/xto706-biosimilars-safety-assessment.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://www.xtalks.com.

For information about hosting a webinar, visit http://www.xtalks.com/sponsorship.ashx.

Contact:
Zayeeta Dasgupta, M.Sc in Life Science and Business Management
1- (416) 977-6555 ext. 260

Read the full story at http://www.prweb.com/releases/2014/01/prweb11484074.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services
2. Pros and Cons of Adaptive Designs: A Leisurely Conversation Between a Clinician and Two Statisticians, New Webinar Hosted by Xtalks
3. A Review of Cardiovascular Pressure Sensing and Relevant Performance Specifications to Ensure Data Integrity, a New and Upcoming Webinar Hosted by Xtalks
4. Catching up with the Genomic Era in Oncology: Key Considerations for Incorporating Genomics into Oncology Drug Development, a New and Upcoming Webinar Hosted by Xtalks
5. Patient-Centric Technology for Better Trial Outcomes, a New and Upcoming Clinical Trial Webinar Hosted by Xtalks
6. UV-C Treatment—a New Procedure for Viral Inactivation, New and Upcoming Webinar Hosted by Xtalks
7. Lessons Learned in Launching a Prognostic Test Based On Tissue Image Analysis, New and Upcoming Webinar Hosted by Xtalks
8. Pharmacovigilance Benefit-Risk Assessments: Requirements, Transparency, and Implications, a New and Upcoming Drug Safety Webinar Hosted by Xtalks
9. Respiratory Update: Interpreting Minimal Clinically Important Differences in COPD and Demonstrating Product Value with PROs, a New Life Science webinar Hosted by Xtalks
10. Pharmacovigilance: ADR Management and Reporting & Outsourcing Trends, A New Drug Safety Webinar from Xtalks
11. Data-driven Site Negotiations: Fast Track to Fair Market Value (FMV), a New Clinical Trials Webinar from Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... , March 24, 2017 Agenus Inc. ... immune checkpoint antibodies and cancer vaccines, today announced participation ... 7 th  Annual William Blair and Maidstone Life Sciences ... Alexandria Center in New York, NY ... March 29 at 9:40 am: Robert B. ...
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
(Date:3/20/2017)... -- At this year,s CeBIT Chancellor Dr. Angela Merkel ... Chancellor came to the DERMALOG stand together with the Japanese Prime Minster ... country. At the largest German biometrics company the two government leaders could ... recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  Continue ... ... to match face pictures against each other or against large databases. The recognition ... ... software for biometric Face Matching on the market. The speed is at 100 ...
Breaking Biology News(10 mins):